Medical device giant Medtronic wins marketing clearance for its 2nd generation Arctic Front cryoablation balloon system with uniform cooling technology.

Medtronic's (NYSE:MDT) expects its newly cleared 2nd generation Arctic Front cryoballoon system to storm clinics in the U.S. and Europe.

The device, indicated for treating an irregular heartbeat, won FDA clearance as well as CE Mark approval in the European Union, the medical device giant announced today.

If it's predecessor was any indication, the device could see rapid adoption among clinicians worldwide.